MSD and Ridgeback Biotherapeutics announce initiation of Pivotal Phase 3 MOVe-AHEAD study evaluating Molnupiravir for Post-Exposure Prophylaxis of COVID-19 infection by admin | Dec 7, 2021 | Healthcare read the full in inquirer.net
